Oral small-molecule (non-peptide) agonist of the glucagon-like peptide-1 (GLP-1) receptor

Orforglipron

Approvedaka LY3502970, Foundayo

Orforglipron is an oral small-molecule GLP-1 receptor agonist that, unlike peptide GLP-1 drugs, can be taken as a daily tablet without strict food and water restrictions. Published Phase 2 trials in obesity and type 2 diabetes showed reductions in body weight and HbA1c, and the Phase 3 program (ATTAIN in obesity and ACHIEVE in type 2 diabetes) reported positive results. On the basis of the ATTAIN obesity program, the US FDA approved orforglipron (Foundayo) in April 2026 for chronic weight management. It is not yet approved for type 2 diabetes and is not yet authorized by the EMA or Australia's TGA.

Compare

Mechanism

In plain terms, orforglipron is a pill that mimics the gut hormone GLP-1, which lowers blood sugar and reduces appetite. Technically, it is a non-peptide small molecule that agonizes the GLP-1 receptor; because it is not a peptide it is orally bioavailable and does not require the injection or the fasting administration constraints of oral peptide GLP-1 drugs. Receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces food intake.

Regulatory Status by Region

  • United States (FDA)Approved. The FDA approved orforglipron (Foundayo) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions, based on the ATTAIN Phase 3 program. A type 2 diabetes indication (ACHIEVE program) is not yet approved.
  • Australia (TGA)Not entered on the Australian Register of Therapeutic Goods (ARTG); not yet approved for supply.
  • European Union (EMA)Not authorized; no marketing authorization at this time.
  • WADANot listed on the WADA Prohibited List. As a GLP-1 receptor agonist it is not a banned substance.

See the full regulatory status matrix

Key Studies

Related Clinical Trials

Related News & Research

Latest research

See all recent Orforglipron research

Common Questions

What is Orforglipron?
Orforglipron is a once-daily oral, non-peptide (small-molecule) GLP-1 receptor agonist from Eli Lilly. The US FDA approved it (brand name Foundayo) in April 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions. It is not yet approved for type 2 diabetes and is not yet authorized by the EMA or Australia's TGA. It is a prescription medicine used under medical supervision.
Is Orforglipron approved for medical use?
Orforglipron is approved for one or more medical uses in at least one major jurisdiction. United States (FDA): Approved. The FDA approved orforglipron (Foundayo) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions, based on the ATTAIN Phase 3 program. A type 2 diabetes indication (ACHIEVE program) is not yet approved. European Union (EMA): Not authorized; no marketing authorization at this time. Australia (TGA): Not entered on the Australian Register of Therapeutic Goods (ARTG); not yet approved for supply.
How does Orforglipron work?
In plain terms, orforglipron is a pill that mimics the gut hormone GLP-1, which lowers blood sugar and reduces appetite. Technically, it is a non-peptide small molecule that agonizes the GLP-1 receptor; because it is not a peptide it is orally bioavailable and does not require the injection or the fasting administration constraints of oral peptide GLP-1 drugs.
Is Orforglipron legal in Australia?
Orforglipron in Australia (TGA): Not entered on the Australian Register of Therapeutic Goods (ARTG); not yet approved for supply.
Is Orforglipron banned in sport?
Orforglipron under the World Anti-Doping Agency (WADA) code: Not listed on the WADA Prohibited List. As a GLP-1 receptor agonist it is not a banned substance.